FDA finally gives thumbs-up to Entereg

GlaxoSmithKline and Adolor reached the Entereg summit. After a four-year climb, the two companies finally got FDA approval to sell the anti-constipation drug Entereg. It's OK'd for use after abdominal surgery, and will be available under a risk-management program designed to prevent long-term outpatient use. The approval was delayed several times when the agency asked for more data, concerned about side effects such as heart problems that might arise with long-term use.

- here's the release on the approval
- see the story in Forbes
- check out the Philadelphia Inquirer article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.